{ "entity_id": "B-004497", "folder": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "type": "Advisory Body", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.health.gov.au/committees-and-groups/australian-brain-cancer-mission-expert-advisory-panel", "data_status": "partial", "completeness": { "has_strategy_brief": true, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": true, "has_kpi_results": false, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_ideas": true, "has_artifacts": true, "n_ideas": 12, "n_legislation": 0, "n_artifacts": 8, "n_kpi_targets": 5, "n_kpi_results": 0, "n_outcomes": 3, "verified_own_data": true }, "strategy_profile": { "status": "needs_review", "confidence": "medium", "summary": "To conduct innovative, interdisciplinary, collaborative and translational preclinical brain cancer research projects that advance knowledge in at least one of these areas:\n• Aetiology of brain cancer;\n• Identification and validation of new therapeutic strategies for brain cancer; and/or\n• Development of new therapies for brain cancer.", "official_site_url": "https://www.health.gov.au/committees-and-groups/australian-brain-cancer-mission-expert-advisory-panel", "source_documents": [ { "type": "strategie", "title": "MRFF Australian Brain Cancer Mission strategic documents [PDF - 269 KB] - 2 pages", "url": "https://www.health.gov.au/sites/default/files/2025-03/mrff-australian-brain-cancer-mission-strategic-documents.pdf", "period": "2025", "confidence": "medium" }, { "type": "strategie", "title": "MRFF Australian Brain Cancer Mission strategic documents [PDF - 479 KB] - 10 pages", "url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "period": "2025", "confidence": "medium" }, { "type": "strategie", "title": "Australian Brain Cancer Research Roadmap [PDF - 354 KB] - 2 pages", "url": "https://www.health.gov.au/sites/default/files/documents/2022/07/australian-brain-cancer-research-roadmap.pdf", "period": "2022", "confidence": "medium" }, { "type": "strategie", "title": "Standard for AI transparency statements", "url": "https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf", "period": "2024", "confidence": "medium" } ], "purpose": null, "vision": null, "strategic_priorities": [], "values": [ { "name": "Innovation", "description": "", "source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "source_page": null }, { "name": "Collaboration", "description": "", "source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "source_page": null }, { "name": "Support for Researchers", "description": "", "source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "source_page": null }, { "name": "Equity", "description": "", "source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "source_page": null } ], "outcomes": [ { "name": "AIM 1: Improve understanding of brain cancer biology", "description": "To conduct innovative, interdisciplinary, collaborative and translational preclinical brain cancer research projects that advance knowledge in at least one of these areas:\n• Aetiology of brain cancer;\n• Identification and validation of new therapeutic strategies for brain cancer; and/or\n• Development of new therapies for brain cancer.", "activities": [ "Conduct innovative, interdisciplinary, collaborative and translational preclinical brain cancer research projects", "Adopt innovative approaches to brain cancer research", "Empower and champion Early- and Mid-Career Researchers", "Involve health care services, including regional, rural and remote health care services" ], "source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "source_page": 4, "source_deep_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=4" }, { "name": "AIM 2: Improve survival for children and adults with brain cancer", "description": "To conduct innovative, interdisciplinary, collaborative and translational pre-clinical and/or early-stage clinical brain cancer research projects that advance knowledge in at least two of these areas:\n• Aetiology of brain cancer;\n• Identification and validation of new therapeutic strategies for brain cancer; and/or\n• Development of new therapies for brain cancer.", "activities": [ "Conduct innovative, interdisciplinary, collaborative and translational pre-clinical and/or early-stage clinical brain cancer research projects", "Adopt innovative approaches to brain cancer research", "Empower and champion Early- and Mid-Career Researchers", "Involve health care services, including regional, rural and remote health care services" ], "source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "source_page": 6, "source_deep_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=6" }, { "name": "AIM 3: Improve quality of life for people affected by brain cancer", "description": "To develop novel approaches to reduce treatment toxicity and adverse effects of brain cancer treatment for patients, to minimise the short- and/or long-term negative impacts for patients and carers.", "activities": [ "Measure the negative impacts of brain cancer treatments", "Improve the quality of life for people affected by brain cancer", "Empower and champion Early- and Mid-Career Researchers", "Involve health care services, including regional, rural and remote health care services" ], "source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "source_page": 7, "source_deep_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=7" } ], "performance_measures": [ { "code": "AIM1-1", "measure": "Understanding the factors associated with the aetiology of brain cancer", "target": "Improve understanding of brain cancer biology", "latest_result": "", "status": "", "target_source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "target_source_page": 4, "result_source_url": "", "result_source_page": null }, { "code": "AIM1-2", "measure": "Understanding factors associated with the mechanisms of treatment resistance", "target": "Improve understanding of brain cancer biology", "latest_result": "", "status": "", "target_source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "target_source_page": 4, "result_source_url": "", "result_source_page": null }, { "code": "AIM2-1", "measure": "Identifying and developing new therapeutic strategies for brain cancer", "target": "Improve survival for children and adults with brain cancer", "latest_result": "", "status": "", "target_source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "target_source_page": 6, "result_source_url": "", "result_source_page": null }, { "code": "AIM2-2", "measure": "Improving diagnostic strategies for disease identification and treatment monitoring", "target": "Improve survival for children and adults with brain cancer", "latest_result": "", "status": "", "target_source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "target_source_page": 6, "result_source_url": "", "result_source_page": null }, { "code": "AIM3-1", "measure": "Creating and evaluating innovative approaches for improving the quality of life of people affected by brain cancer", "target": "Improve quality of life for people affected by brain cancer", "latest_result": "", "status": "", "target_source_url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "target_source_page": 7, "result_source_url": "", "result_source_page": null } ], "document_alignment_terms": { "must_support": [], "watch_terms": [ "Understanding the factors associated with the aetiology of brain cancer", "Understanding factors associated with the mechanisms of treatment resistance", "Identifying and developing new therapeutic strategies for brain cancer", "Improving diagnostic strategies for disease identification and treatment monitoring", "Creating and evaluating innovative approaches for improving the quality of life of people affected by brain cancer" ], "avoid_claiming_without_evidence": [] }, "review_note": "Structured strategy exists but is incomplete." }, "strategy_brief_md": "# MRFF Australian Brain Cancer Mission Expert Advisory Panel — Strategy Brief\n\n**Reporting period**: 2024-25\n**Corporate plan in force**: 2025-26\n**Corporate Plan**: [2025-26](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf)\n\n## Outcomes\n\n### AIM 1: Improve understanding of brain cancer biology\nTo conduct innovative, interdisciplinary, collaborative and translational preclinical brain cancer research projects that advance knowledge in at least one of these areas:\n• Aetiology of brain cancer;\n• Identification and validation of new therapeutic strategies for brain cancer; and/or\n• Development of new therapies for brain cancer. [[CP p.4](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=4)]\n\n**Key activities:**\n- Conduct innovative, interdisciplinary, collaborative and translational preclinical brain cancer research projects\n- Adopt innovative approaches to brain cancer research\n- Empower and champion Early- and Mid-Career Researchers\n- Involve health care services, including regional, rural and remote health care services\n\n### AIM 2: Improve survival for children and adults with brain cancer\nTo conduct innovative, interdisciplinary, collaborative and translational pre-clinical and/or early-stage clinical brain cancer research projects that advance knowledge in at least two of these areas:\n• Aetiology of brain cancer;\n• Identification and validation of new therapeutic strategies for brain cancer; and/or\n• Development of new therapies for brain cancer. [[CP p.6](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=6)]\n\n**Key activities:**\n- Conduct innovative, interdisciplinary, collaborative and translational pre-clinical and/or early-stage clinical brain cancer research projects\n- Adopt innovative approaches to brain cancer research\n- Empower and champion Early- and Mid-Career Researchers\n- Involve health care services, including regional, rural and remote health care services\n\n### AIM 3: Improve quality of life for people affected by brain cancer\nTo develop novel approaches to reduce treatment toxicity and adverse effects of brain cancer treatment for patients, to minimise the short- and/or long-term negative impacts for patients and carers. [[CP p.7](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=7)]\n\n**Key activities:**\n- Measure the negative impacts of brain cancer treatments\n- Improve the quality of life for people affected by brain cancer\n- Empower and champion Early- and Mid-Career Researchers\n- Involve health care services, including regional, rural and remote health care services\n\n## Values and principles\n\n_Not specified_\n\n- Innovation\n- Collaboration\n- Support for Researchers\n- Equity\n\n## What they will measure themselves on this year (targets from 2025-26 corporate plan)\n\n| Code | Measure | Target | Source |\n|---|---|---|---|\n| AIM1-1 | Understanding the factors associated with the aetiology of brain cancer | Improve understanding of brain cancer biology | [CP p.4](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=4) |\n| AIM1-2 | Understanding factors associated with the mechanisms of treatment resistance | Improve understanding of brain cancer biology | [CP p.4](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=4) |\n| AIM2-1 | Identifying and developing new therapeutic strategies for brain cancer | Improve survival for children and adults with brain cancer | [CP p.6](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=6) |\n| AIM2-2 | Improving diagnostic strategies for disease identification and treatment monitoring | Improve survival for children and adults with brain cancer | [CP p.6](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=6) |\n| AIM3-1 | Creating and evaluating innovative approaches for improving the quality of life of people affected by brain cancer | Improve quality of life for people affected by brain cancer | [CP p.7](https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf#page=7) |", "strategy_overview_evidence_md": null, "internal_strategy_evidence_md": "# MRFF Australian Brain Cancer Mission Expert Advisory Panel - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:40:37.298624+00:00\n**Entity ID**: B-004497\n**Entity type**: Advisory Body\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: https://www.health.gov.au/committees-and-groups/australian-brain-cancer-mission-expert-advisory-panel\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| other-pdfs | 4 |\n| pages | 26 |\n| strategies | 4 |\n\n## Executive Readout\n\n### Purpose\n\n- Development of an evaluation and stakeholder management plan\nAn evaluation and stakeholder management plan were developed for this review which:\n■ set out a fit-for-purpose program logic (see chart 1.4) that aligns with the MRFF\nMonitoring, Evaluation and Learning Strategy 2021-22 to 2023-24 (Evaluation\nStrategy) to review progress towards MRFF outcome and impact measures, and\nalignment with the goals and priorities of the Mission\n■ provided a search strategy for the literature review to support an environmental scan\nof the brain cancer research landscape\n■ identified how literature would be collated and assessed to draw insight for the\npurpose of the Mission evaluation, and\n■ set out a proposed consultation strategy, including the type of information to be\ncollected from surveys, and from semi-structured interviews.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 6]\nvi\nReview of the Australian Brain Cancer Mission\n4.11 Likelihood that new technologies will be commercialised 83\n5.1 Opportunity #1: Defining the role and purpose of the Mission 86\n5.2 Opportunity #2: Developing and Implementation Plan 87\n5.3 Opportunity #2.1: Improved communication and coordination with\nMission stakeholders 89\n5.4 Opportunity #2.2: Increased funding for biology and basic research 90\n5.5 Opportunity #2.3: Innovated funding to retain early and mid-stage\nresearchers and clinician researchers 91\n5.6 Opportunity #2.4: Alternative innovating funding models 93\n5.7 Opportunity #2.5: Encouraging greater Industry involvement 94\n5.8 Opportunity #2.6: Aligning future funding with best role for the Mission 95\n5.9 Opportunity #2.7: Consumer engagement framework 96\n5.10 Opportunity #3: Improvements to the competitive grants model 97\nA.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 10]\n4\nReview of the Australian Brain Cancer Mission\n1 Overview of the review\nThe purpose of this review in line with the Terms of Reference is to:\n■ assess all existing investments under the Mission through the MRFF and partner\nfunding3 from October 2017 to April 2022\n■ assess all other existing investments in brain cancer research made through the\nMRFF from October 2017 to April 2022\n■ consider approaches and the current landscape for health and medical research and\ntreatments for brain cancer internationally and in Australia, and\n■ suggest opportunities (if any) for improving alignment between the intended goals\nand implementation of the Mission.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- A.2 Mission 2018 targeted grants awarded\nGrant Objectives Expected outcomes\nopportunity\n2018 To improve therapy and outcomes for The expected outcomes of the Program are:\nEnhanced children with brain cancer through\n■ Development and implementation of an Australian\nCapacity of the Australian-based access to innovative and\nResearch Agenda that identifies current and\nAustralian and cutting-edge approaches with the aim of\nupcoming leading international trials of high\nNew Zealand pursuing research breakthroughs.\npotential relevance/ significance to Australian brain\nChildren’s\nThe objectives of the ANZCHOG Grant cancer patients\nHaematology\nOpportunity are to:\nOncology ■ Enabled participation and expedited time to start-up\nGroup ■ Enhance the capacity of ANZCHOG to in Australia of approved trials by identifying the most\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n\n### Role and Functions\n\n- Although Funding\nPartners are unlikely to cede control over their investment decisions, there may be a\nrole for the Mission to achieve better co-ordination across funders.\n■ Should Mission funding be scaling up validated new ideas with no role in basic\nresearch?\n■ Should the Mission have a Board with strategic responsibilities, rather than a body\nwith advisory capacity only?\n■ Should the Mission be a vehicle for funding larger projects only?\n■ Should Cancer Australia or the Department of Health and Aged Care as co-\nadministrators of the Mission have a strategic priority to champion Australia as a\ndestination for clinical trials where it can be more competitive (such as in Phase 0 and\nPhase 1 adult clinical trials) and/or find innovative ways for Australian patients to\naccess international Phase 2 and Phase 3 trials?\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 6]\nFunding\nFunding Partner investment Institution contribution\n(million)\nUnrestricted research grant (Snow Ball Donation) Tour de Cure $0.03\nUnrestricted research grant (matched fundraising) Cure Brain Cancer Foundation $0.20\nUnrestricted research grant (matched fundraising) Cure Brain Cancer Foundation $0.30\nUnrestricted research grant (Charlie Teo WA Ball Donation) Charlie Teo Foundation $0.20\nNeuroSurgical Research Foundation\nImmunotherapy Glioblastoma (CAR)-T Dr Lisa Ebert University of South Australia $0.06\nA new approach to deliver drugs to brain tumours Dr Briony Gliddon University of South Australia $0.06\nBrain organoids for rapid and personalised pre-clinical test of treatments for GBM Dr Guillermo Gomez University of South Australia $0.06\nDeveloping a comprehensive glioblastoma brain tumour database Dr Melinda Tea University of South Australia $0.03\n Source: `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)`\n- [Page 6]\nvi\nReview of the Australian Brain Cancer Mission\n4.11 Likelihood that new technologies will be commercialised 83\n5.1 Opportunity #1: Defining the role and purpose of the Mission 86\n5.2 Opportunity #2: Developing and Implementation Plan 87\n5.3 Opportunity #2.1: Improved communication and coordination with\nMission stakeholders 89\n5.4 Opportunity #2.2: Increased funding for biology and basic research 90\n5.5 Opportunity #2.3: Innovated funding to retain early and mid-stage\nresearchers and clinician researchers 91\n5.6 Opportunity #2.4: Alternative innovating funding models 93\n5.7 Opportunity #2.5: Encouraging greater Industry involvement 94\n5.8 Opportunity #2.6: Aligning future funding with best role for the Mission 95\n5.9 Opportunity #2.7: Consumer engagement framework 96\n5.10 Opportunity #3: Improvements to the competitive grants model 97\nA.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- What we do\nRead about our role and responsibilities in the areas of health technologies and digital health.\n Source: `pages/strategies-index__10.html (https://www.health.gov.au/topics/health-technologies-and-digital-health?language=en)`\n- [pages 20,21,22]\nty #1 Defining the role and purpose of the Mission\nIt is recommended that the Australian Government, with advice from an advisory panel\nfor the Mission, Cancer Australia, and the Department of Health and Aged Care form a\nview about the charter of the Mission, and communicate this to stakeholders who can\nthen align their expectations with what the Mission is best placed to do and represent.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 78]\n72\nReview of the Australian Brain Cancer Mission\nChart 4.5 shows the potential impacts that researchers expect these new technologies will\ndeliver (as well as the researchers’ assessment of the level of certainty with which a new\ntechnology will be delivered).\n■ 7 projects are expected (certain, very likely or likely) to deliver a new technology that\nwill improve the chance of survival (although the extent of the improvement is not\nknown)\n■ 7 projects are expected to deliver a new technology that will lead to ‘other\nimprovements’ (i.e. excluding reduced impact on cognitive function, reduced pain and\nreduced fatigue) in health-related quality of life for patients\n■ 6 projects are expected to deliver a new technology that will reduce the burden on the\nhealth system.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n\n### Strategic Priorities\n\n- Although Funding\nPartners are unlikely to cede control over their investment decisions, there may be a\nrole for the Mission to achieve better co-ordination across funders.\n■ Should Mission funding be scaling up validated new ideas with no role in basic\nresearch?\n■ Should the Mission have a Board with strategic responsibilities, rather than a body\nwith advisory capacity only?\n■ Should the Mission be a vehicle for funding larger projects only?\n■ Should Cancer Australia or the Department of Health and Aged Care as co-\nadministrators of the Mission have a strategic priority to champion Australia as a\ndestination for clinical trials where it can be more competitive (such as in Phase 0 and\nPhase 1 adult clinical trials) and/or find innovative ways for Australian patients to\naccess international Phase 2 and Phase 3 trials?\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- 3.4 Summary of other MRFF grants for brain cancer research\n- Grants Amount\n- No. $\nClinical Trials Activity\n2018 Rare Cancers, Rare Diseases and Unmet Need - General 4 3 016 742\n2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancers 3 2 332 299\n2021 Rare Cancers, Rare Diseases and Unmet Need 1 1 982 681\nTotal - Clinical Trials Activity 8 7 331 723\nEmerging Priorities and Consumer Driven Research\n2018 Accelerated Research - Priority-driven Collaborative Cancer Research 2 958 215\nScheme - All Cancers\n2018 Accelerated Research - Priority-driven Collaborative Cancer Research 1 480 015\nScheme - Childhood Cancers of Low Survival\nTotal - Emerging Priorities and Consumer Driven Research 3 1 438 231\nSource: HMRO, CIE.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- A.1 MRFF grants for brain cancer research — summary\n- Grants Amount\n- No. $\nAustralian Brain Cancer Mission\n2018 Enhanced Capacity of the Australian and New Zealand Children’s 1 3 010 000\nHaematology Oncology Group (ANZCHOG) Program\n2018 Enhanced Capacity of the Cooperative Trials Group for Neuro-Oncology 1 2 500 000\n(COGNO) Program\n2018 ZERO Childhood Brain Cancer 1 5 002 023\n2019 Brain Cancer Survivorship 2 6 914 602\n2019 Innovative Clinical Trials 2 1 749 170\n2020 Brain Cancer Survivorship 1 2 615 278\nTotal - Mission 8 $21 791 073\nClinical Trials Activity\n2018 Rare Cancers, Rare Diseases and Unmet Need - General 4 3 016 742\n2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancers 3 2 332 299\n2021 Rare Cancers, Rare Diseases and Unmet Need 1 1 982 681\nTotal - Clinical Trials Activity 8 7 331 723\nEmerging Priorities and Consumer Driven Research\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [pages 109,110,111]\novative Clinical Trials 2 1 749 170\n2020 Brain Cancer Survivorship 1 2 615 278\nTotal - Mission 8 $21 791 073\nClinical Trials Activity\n2018 Rare Cancers, Rare Diseases and Unmet Need - General 4 3 016 742\n2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancers 3 2 332 299\n2021 Rare Cancers, Rare Diseases and Unmet Need 1 1 982 681\nTotal - Clinical Trials Activity 8 7 331 723\nEmerging Priorities and Consumer Driven Research\n2018 Accelerated Research - Priority-driven Collaborative Cancer Research 2 958 215\nScheme - All Cancers\n72 Since April 2022, 4 grants have been awarded worth $11.45m, which includes two additional\nlead organisations (The Walter and Eliza Hall Institute of Medical Research and The Council\nof the Queensland Institute of Medical Research)\nwww.TheCIE.com.au\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 110]\n104\nReview of the Australian Brain Cancer Mission\n- Grants Amount\n- No. $\n2018 Accelerated Research - Priority-driven Collaborative Cancer Research 1 480 015\nScheme - Childhood Cancers of Low Survival\nTotal - Emerging Priorities and Consumer Driven Research 3 1 438 231\nTotal 19 $30 561 027\nSource: Health and Medical Research Office, CIE.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 2]\nFunded from\nAmount (ex\nInstitution Project Title Grant\nGST)\nOpportunity\nImplementation Plan Priority Area 2.1\nUniversity of New South Wales Zero Childhood Brain Cancer program $5,002,023.00 3\nLUMOS (Low & Intermediate Grade Glioma Umbrella Study of Molecular\nUniversity of Sydney $502,558.00 5\nGuided Therapies)\nA new targeted combination therapy with matched biomarker to treat\nUniversity of New South Wales $582,686.40 7\nintractable glioblastoma\nThe Walter and Eliza Hall Institute “GLIMMER” - Glioma Liquid biopsy and Multiomic-Monitoring Enabled\n$4,550,471.30 7\nof Medical Research Research platform\nThe Council of the Queensland\n“Off-the-shelf” CAR-T cell immunotherapy for brain cancer $329,489.00 7\nInstitute of Medical Research\nImplementation Plan Priority Area 2.2\nProspective, multicentre trial evaluating FET-PET in high grade glioma (FIG\nLa Trobe University $1,246,611.80 5\n Source: `other-pdfs/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november_2024.pdf)`\n- Development of an evaluation and stakeholder management plan\nAn evaluation and stakeholder management plan were developed for this review which:\n■ set out a fit-for-purpose program logic (see chart 1.4) that aligns with the MRFF\nMonitoring, Evaluation and Learning Strategy 2021-22 to 2023-24 (Evaluation\nStrategy) to review progress towards MRFF outcome and impact measures, and\nalignment with the goals and priorities of the Mission\n■ provided a search strategy for the literature review to support an environmental scan\nof the brain cancer research landscape\n■ identified how literature would be collated and assessed to draw insight for the\npurpose of the Mission evaluation, and\n■ set out a proposed consultation strategy, including the type of information to be\ncollected from surveys, and from semi-structured interviews.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Access the report\nNews\nNews\nWebinar: Sex, gender, variations of sex characteristics and sexual orientation in health and medical research\n17 November 2025\nExpress your interest in guiding the Medical Research Future Fund’s Reducing Health Inequities Mission\n19 August 2025\nMedical Research Future Fund: Supporting researchers to tackle Australia’s health priorities\n11 August 2025\nView more news\nRelated work\nRelated work\nCo-design of an Enhanced Consumer Engagement Process for Health Technology Assessment\nThis process developed recommendations to include the patient and consumer voice earlier in the Health Technology Assessment (HTA) process.\n Source: `pages/strategies-index__10.html (https://www.health.gov.au/topics/health-technologies-and-digital-health?language=en)`\n- This is expected to include:\n■ the Mission goal\n■ priority areas for investment\n■ delivery horizons, including research to be actioned in the short (1-2 years) and\nmedium term (2-5 years), and potentially longer term expectations beyond the current\nfunded period, and\n■ activities / amendments required to support research and facilitate aspirational\noutcomes.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 23]\nReview of the Australian Brain Cancer Mission\n17\nOpportunity #2.4: Alternative innovating funding models\nThe standard competitive funding model alone is unlikely to be able to achieve some of\nthe strategic priorities of the Mission.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n\n## KPIs, Targets, and Where They Are At\n\n- 0\n0\n3\n3\nf th\ne\nA\nu\ns tra\nlia\nn\nB\nra\nResearch grant Genetically engineered invariant NKT cells for dual University of Adelaide 0.05 in\nC\ntargeting of DIPG Ms Kristyna Sedivakova a\nn\nc\ne\nResearch grant Pioneering unique models of all glioblastoma subtypes to Flinders University 0.04\nr\nM\nis\nimprove brain cancer treatment Dr Brett Stringer s io\nn\nResearch grant Predicting chemotherapeutic neurotoxicity with Flinders University 0.04\nelectrophysiological and morphological assays of human\nbrain tissue in vitro A/Prof Cedric Bardy\nResearch grant Inhibiting ER-stress induced CD47 to treat glioblastoma University of South 0.04\nDr Nirmal Robinson Australia\nResearch grant Harnessing S1P receptor 1 to enhance CAR-T cell University of South 0.04\nimmunotherapy for glioblastoma Dr Briony Gliddon Australia\nResearch grant A novel technique for defining brain tumours on MRI Dr University of South 0.04\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [pages 122,123,124,125]\ning brain tumours on MRI Dr University of South 0.04\nMinh-Son To Australia\nResearch grant Identifying mechanisms that guide T cells into tumours to University of South 0.04\nimprove CAR-T cell therapy for glioblastoma Dr Lisa Ebert Australia\nResearch grant Use of artificial intelligence to identify glioblastoma University of South 0.04\npatients that respond favourably to therapy Dr Guillermo Australia\nGomez\nResearch grant FAPi-MRI towards better target delineation of high-grade University of South 0.03\ngliomas Prof Benjamin Thierry Australia\nResearch grant Initiation of the KARPOS clinical trial to treat GBM (CAR-T University of South 0.05\ncells) A/Prof Lisa Ebert Australia\nResearch grant Evaluating CD47 regulated mechanisms to treat GBM Dr University of South 0.05\nNirmal Robinson Australia\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 2]\nFunding\nFunding Partner investment Institution contribution\n(million)\nThe Brain Cancer Centre WEHI $4.00\nChildren's Hospital Foundation Queensland\nExploiting CDK 4/6 inhibition to treat medulloblastoma University of Queensland $0.20\nNew strategies for targeting immune evasion in children's brain tumours University of Queensland $0.10\nIntegrating innovative models of the brain microenvironment to identify new treatment strategies for\nUniversity of Queensland $0.05\nmedulloblastoma\nThe University of Queensland;\nUnallocated - research tbc Queensland; University of $1.11\nTechnology; QIMR Berghofer & CHQ\nAssessment of the Novel OLIG2 Inhibitor CT179 as an EffectiveTherapy for Paediatric Medulloblastoma QIMR Berghofer $0.50\nEphA3 a Valid Tumour Specific Therapeutic Target for Paediatric Brain Cancer QIMR Berghofer $0.53\nQueensland University of\n Source: `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)`\n- [Page 7]\nFunding\nFunding Partner investment Institution contribution\n(million)\nGenetically engineered invariant NKT cells for dual targeting of DIPG Ms Kristyna Sedivakova University of Adelaide $0.05\nPioneering unique models of all glioblastoma subtypes to improve brain cancer treatment Dr Brett Stringer Flinders University $0.04\nPredicting chemotherapeutic neurotoxicity with electrophysiological and morphological assays of human\nFlinders University $0.04\nbrain tissue in vitro A/Prof Cedric Bardy\nInhibiting ER-stress induced CD47 to treat glioblastoma Dr Nirmal Robinson University of South Australia $0.04\nHarnessing S1P receptor 1 to enhance CAR-T cell immunotherapy for glioblastoma Dr Briony Gliddon University of South Australia $0.04\nA novel technique for defining brain tumours on MRI Dr Minh-Son To University of South Australia $0.04\n Source: `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)`\n- [pages 7,8,9,10]\n.04\nGomez\nFAPi-MRI towards better target delineation of high-grade gliomas Prof Benjamin Thierry University of South Australia $0.03\nInitiation of the KARPOS clinical trial to treat GBM (CAR-T cells) A/Prof Lisa Ebert University of South Australia $0.05\nEvaluating CD47 regulated mechanisms to treat GBM Dr Nirmal Robinson University of South Australia $0.05\nA new approach to enhance immunotherapy for GBM Dr Melinda Tea University of South Australia $0.05\nRoles of sphingosine kinase 1 and 2 in GBM Dr Briony Gliddon University of South Australia $0.05\nLimiting invasive capabilities of GBM cells Dr Sunita Ramesh Flinders University $0.03\nMembrane-cholesterol depleting agents o and anti-glioma cytolytic activity of GD2- specific CAR-T cells Dr\nUniversity of South Australia $0.04\nMichael Brown\n7\n Source: `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)`\n- The work has led to the 2021 publication\nof ‘Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively\neliminate human glioblastoma’98 and the 2020 publication of ‘De novo designed receptor\ntransmembrane domains enhance CAR-T cell cytotoxicity and attenuate cytokine release’99\n■ Genetic research — seeking more information about specific gene mutations and how\nthey relate to the risk and growth of a brain tumour so that precision medicine\napproaches that target tumour-specific mutations can be explored.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- [pages 1,2,3,4,5]\n[Page 1]\nDeclarations of Interest Policy Statement\nPurpose\nTo ensure members of MRFF advisory panels, committees, groups and other bodies identify\nand declare relevant interests and that the Health and Medical Research Office (HMRO)\nmanages these interests appropriately.\n Source: `other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf (https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf)`\n- [Page 6]\nvi\nReview of the Australian Brain Cancer Mission\n4.11 Likelihood that new technologies will be commercialised 83\n5.1 Opportunity #1: Defining the role and purpose of the Mission 86\n5.2 Opportunity #2: Developing and Implementation Plan 87\n5.3 Opportunity #2.1: Improved communication and coordination with\nMission stakeholders 89\n5.4 Opportunity #2.2: Increased funding for biology and basic research 90\n5.5 Opportunity #2.3: Innovated funding to retain early and mid-stage\nresearchers and clinician researchers 91\n5.6 Opportunity #2.4: Alternative innovating funding models 93\n5.7 Opportunity #2.5: Encouraging greater Industry involvement 94\n5.8 Opportunity #2.6: Aligning future funding with best role for the Mission 95\n5.9 Opportunity #2.7: Consumer engagement framework 96\n5.10 Opportunity #3: Improvements to the competitive grants model 97\nA.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 10]\n4\nReview of the Australian Brain Cancer Mission\n1 Overview of the review\nThe purpose of this review in line with the Terms of Reference is to:\n■ assess all existing investments under the Mission through the MRFF and partner\nfunding3 from October 2017 to April 2022\n■ assess all other existing investments in brain cancer research made through the\nMRFF from October 2017 to April 2022\n■ consider approaches and the current landscape for health and medical research and\ntreatments for brain cancer internationally and in Australia, and\n■ suggest opportunities (if any) for improving alignment between the intended goals\nand implementation of the Mission.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Survival is\nparticularly poor for certain brain cancer types, with the five year survival rate for\nglioblastoma being 4.6 per cent.22\nThe relatively minimal progress in survival reflects the absence of substantive change in\nthe treatment regime for brain cancer in the last 30 years, and treatments that do exist,\nresult often result in a range of physical and mental health problems.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 49]\nReview of the Australian Brain Cancer Mission\n43\n2.12 Funds committed by funding categories — Funding Partners\n- Amount committed Share of total\n- $ million Per cent\nCentres of Excellence 26.03 35\nClinical trials 13.01 18\nClinical trial capacity 6.65 9\nEquipment grant 5.06 7\nFellowships 3.07 4\nResearch chairs 1.00 1\nResearch grants 16.12 22\nStaff 0.36 0\nTechnology research 2.02 3\nOther 0.65 1\nTotal 73.97 100\nNote: The relevant information is not available for all Funding Partners .\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- 3.4 Summary of other MRFF grants for brain cancer research\n- Grants Amount\n- No. $\nClinical Trials Activity\n2018 Rare Cancers, Rare Diseases and Unmet Need - General 4 3 016 742\n2019 Rare Cancers, Rare Diseases and Unmet Need - Childhood Brain Cancers 3 2 332 299\n2021 Rare Cancers, Rare Diseases and Unmet Need 1 1 982 681\nTotal - Clinical Trials Activity 8 7 331 723\nEmerging Priorities and Consumer Driven Research\n2018 Accelerated Research - Priority-driven Collaborative Cancer Research 2 958 215\nScheme - All Cancers\n2018 Accelerated Research - Priority-driven Collaborative Cancer Research 1 480 015\nScheme - Childhood Cancers of Low Survival\nTotal - Emerging Priorities and Consumer Driven Research 3 1 438 231\nSource: HMRO, CIE.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $23 million, 23 million | Securing the NDIS for future generations\n22 April 2026\nNews\nThe Australian Government is taking steps to protect the National Disability Insurance Scheme (NDIS) for people with permanent and significant disability and for future generations who will rely on it.\n$23 million for research into Post-Acute Sequelae of COVID-19\n13 April 2026\nNews\nApply for the latest Medical Research Future Fund (MRFF) grant opportunity. | `pages/news-latest.html (https://www.health.gov.au/news)` |\n| $136.66 million, $60.26 million, 136.66 million, 60.26 million | [Page 11]\nReview of the Australian Brain Cancer Mission\n5\nTogether, the Mission funders have committed $136.66 million to invest in Australian\nbrain cancer research, $60.26 million of which is via the MRFF. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $136.66 million, $50 million, $10.26 million, $76.4 million, 136.66 million, 50 million | The combined efforts of the MRFF and the Mission Funding Partners represent the\nlargest pooled allocation of funding to brain cancer research in Australian history, which\nsince 2017-18 has committed $136.66 million over 10 years, including:\n■ $50 million from the Australian Government to be distributed via the Mission\n■ $10.26 million from the Australian Government via other MRFF initiatives, and\n■ $76.4 million through Funding Partners. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $1.5 million, 1.5 million | Based on the 2023 Cancer Australia audit of cancer research in Australia, in 2003-2005,\n$1.5 million was allocated to 10 brain cancer specific projects. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $54.1 million, 54.1 million | With some increases in\nsubsequent years, the 2018-2020 period witnessed a large increase in brain cancer\nresearch with $54.1 million allocated to over 161 projects (chart 2). | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $54.1 million, 54.1 million | [pages 11,12,13]\nyears, the 2018-2020 period witnessed a large increase in brain cancer\nresearch with $54.1 million allocated to over 161 projects (chart 2). | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $21.8 million, 21.8 million, 44 per cent | From 2017 up until April 20226,\n8 grants were allocated through the Mission totalling $21.8 million (44 per cent of the\ntotal to be allocated through the Mission). | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $10.5 million, $11.3 million, $10.26 million, 10.5 million, 11.3 million, 10.26 million | This included:\n– 3 directed grants with a total value of $10.5 million, and\n– 5 competitive grants allocated through 3 competitive grant opportunities with a\ntotal value of $11.3 million.\n■ $10.26 million will be allocated through other MRFF initiatives. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $33.24 million, 33.24 million, 67 per cent | From 2017 up until\nJuly 2023, 12 grants were allocated through the Mission totalling $33.24 million\n(67 per cent of the total to be allocated through the Mission). | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $10.5 million, $22.8 million, $10.26 million, 10.5 million, 22.8 million, 10.26 million | This included:\n– 3 directed grants with a total value of $10.5 million\n– 9 competitive grants with a total value of $22.8 million, and\n■ A further $10.26 million will be allocated through other MRFF initiatives. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $54.1 million, 54.1 million | With some steady increases in subsequent\nyears, the 2018-2020 period witnessed a substantial increase in brain cancer research with\n$54.1 million allocated to over 161 projects (chart 2.1). | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $136.66 million, $50 million, $76.4 million, $10.26 million, 136.66 million, 50 million | The combined efforts of the MRFF and the Mission Funding Partners represent the\nlargest pooled investment of brain cancer research in Australian history, which since\n2017-18 has committed $136.66 million, including:\n■ $50 million from the Australian Government to be distributed via the Mission36\n■ $76.4 million through Funding Partners, and\n■ $10.26 million from the Australian Government distributed via other MRFF\ninitiatives37. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $25 million, 25 million | 36 Includes $25 million allocated in the updated 10-year investment plan from 2022-23 to 2026-27. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $136.66 million, $50 million, $76.4 million, $10.26 million, 136.66 million, 50 million | [pages 41,42,43]\nhich since\n2017-18 has committed $136.66 million, including:\n■ $50 million from the Australian Government to be distributed via the Mission36\n■ $76.4 million through Funding Partners, and\n■ $10.26 million from the Australian Government distributed via other MRFF\ninitiatives37. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $5.6 million, 5.6 million | It committed\n$5.6 million to the Mission which is used to fund the Children’s Brain Cancer Centre\nover 5 years.\n■ Cure Brain Cancer Foundation, which contributes funds towards the Zero\nChildhood Cancer Program (ZERO), the Cure Brain Cancer Neuro-Oncology Group\nat the University of New South Wales (UNSW), GBM AGILE and other clinical\ntrials, such as:\n– INTELLANCE 2 for patients with glioblastoma45\n– the KB004 clinical trial to prove the drug cross | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $33.2 million, 33.2 million | From 2017 up until\nJuly 2023, 12 grants were allocated through the Mission totalling $33.2 million (67 per\ncent of the total to be allocated through the Mission). | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $1.6 million, $2.7 million, $800 , $390 , $50 , $1 million | In general, apart from the\nlarger philanthropic organisations, research grants (including grants identified as clinical\ntrials or other research grants, but excluding funding for Centres of Excellence) tended to\nbe significantly smaller than those provided by the MRFF.\n■ The average grant provided through the MRFF is $1.6 million included:\n– an average of $2.7 million for those provided through the Mission\n– an average of around $800 000 for thos | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $1 million, 10 per cent, 1 million | [pages 68,69,70]\n50 000 (table 3.13).\n– Less than 10 per cent of grants provided by Funding Partners were more than\n$1 million. | `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)` |\n| $4.00\n, $0.20\n, $0.10\n, $0.05\nm, $1.11\n, $0.50 | [Page 2]\nFunding\nFunding Partner investment Institution contribution\n(million)\nThe Brain Cancer Centre WEHI $4.00\nChildren's Hospital Foundation Queensland\nExploiting CDK 4/6 inhibition to treat medulloblastoma University of Queensland $0.20\nNew strategies for targeting immune evasion in children's brain tumours University of Queensland $0.10\nIntegrating innovative models of the brain microenvironment to identify new treatment strategies for\nUniv | `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)` |\n| $0.05\n, $0.04\n, $0.04 | [Page 7]\nFunding\nFunding Partner investment Institution contribution\n(million)\nGenetically engineered invariant NKT cells for dual targeting of DIPG Ms Kristyna Sedivakova University of Adelaide $0.05\nPioneering unique models of all glioblastoma subtypes to improve brain cancer treatment Dr Brett Stringer Flinders University $0.04\nPredicting chemotherapeutic neurotoxicity with electrophysiological and morphological assays of human\nFlinders Univer | `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)` |\n\n## Key Achievements\n\n- [Page 3]\nReview of the Australian Brain Cancer Mission\niii\nContents\nGlossary 1\nSummary 3\nAbout the Australian Brain Cancer Mission 3\nOverview of the Australian brain cancer research landscape 5\nMission progress and key achievements to date 10\nKey opportunities 14\nResearch qualifications and limitations 18\n1 Introduction 20\nUnmet need in brain cancer research 20\nThe Australian Brain Cancer Mission 21\nAbout this review 25\nMethodology 27\nResearch qualifications and limitations 28\n2 Local and international approaches to research 30\nOverview of Australian brain cancer research 30\nFunders of Australian brain cancer research 34\nAustralian research affiliations 45\nFunding models for Australian brain cancer research 48\nComparisons with international brain cancer research 51\n3 Mission and other MRFF brain cancer research 53\nMRFF-funded brain cancer research 53\nFocus on collaboration 56\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Development of an evaluation and stakeholder management plan\nAn evaluation and stakeholder management plan were developed for this review which:\n■ set out a fit-for-purpose program logic (see chart 1.4) that aligns with the MRFF\nMonitoring, Evaluation and Learning Strategy 2021-22 to 2023-24 (Evaluation\nStrategy) to review progress towards MRFF outcome and impact measures, and\nalignment with the goals and priorities of the Mission\n■ provided a search strategy for the literature review to support an environmental scan\nof the brain cancer research landscape\n■ identified how literature would be collated and assessed to draw insight for the\npurpose of the Mission evaluation, and\n■ set out a proposed consultation strategy, including the type of information to be\ncollected from surveys, and from semi-structured interviews.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 77]\nReview of the Australian Brain Cancer Mission\n71\n4.3 Types of new health technologies developed through MRFF brain cancer grants\nHealth assessment tool for late effects of childhood\nbrain cancer\nDistance-delivered health assessment for late\neffects of childhood brain cancer\nSupportive care pathways & screening systems\nCombination of new drug with standard of care\ntherapy\nNew ongoing treatments for survivors\nNew prognostic technique\nNew diagnostic tool/approach\nOther new brain cancer treatment\nNew use of an existing drug to treat the relevant\nbrain cancer\nNew drug to treat brain cancer\n0 1 2 3 4 5\nNumber of projects\nData source: CIE survey.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 78]\n72\nReview of the Australian Brain Cancer Mission\nChart 4.5 shows the potential impacts that researchers expect these new technologies will\ndeliver (as well as the researchers’ assessment of the level of certainty with which a new\ntechnology will be delivered).\n■ 7 projects are expected (certain, very likely or likely) to deliver a new technology that\nwill improve the chance of survival (although the extent of the improvement is not\nknown)\n■ 7 projects are expected to deliver a new technology that will lead to ‘other\nimprovements’ (i.e. excluding reduced impact on cognitive function, reduced pain and\nreduced fatigue) in health-related quality of life for patients\n■ 6 projects are expected to deliver a new technology that will reduce the burden on the\nhealth system.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Survey of grant recipients\nThe purpose of the survey of grant recipients was to:\n■ assess the extent to which MRFF grants aligned with the Mission Roadmap\n■ assess the progress that MRFF have made towards achieving the MRFF ‘Measures of\nSuccess’ and MRFF ‘Impact Measures’ as set out in the MRFF Monitoring,\nEvaluation and Learning Strategy 2021-22 to 2023-24 (the Evaluation Strategy), and\n■ provide insights into other matters relevant to the review of the Mission, including\nwhether MRFF grants enabled research institutions to undertake more brain cancer\nresearch, whether MRFF grants encouraged collaboration with researchers within\nAustralia and internationally, and the extent of engagement with consumer groups.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- View all information about the department\nLatest news\nLatest news\nBudget 2025–26 information\n25 March 2025\nDepartment of Health and Aged Care Statement\nProfessor Michael Kidd AO, MBBS, MD, FAHMS, FRACGP has been appointed as Australia’s new Chief Medical Officer from 1 June 2025.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- 19 March 2025\nBudget 2024–25 information\n14 May 2024\nView more corporate news\nCorporate initiatives and programs\nGraduate Program\nOur graduate program starts in February each year and is based in Canberra.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- [pages 1,2,3,4,5]\n[Page 1]\nDeclarations of Interest Policy Statement\nPurpose\nTo ensure members of MRFF advisory panels, committees, groups and other bodies identify\nand declare relevant interests and that the Health and Medical Research Office (HMRO)\nmanages these interests appropriately.\n Source: `other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf (https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf)`\n- [Page 6]\nvi\nReview of the Australian Brain Cancer Mission\n4.11 Likelihood that new technologies will be commercialised 83\n5.1 Opportunity #1: Defining the role and purpose of the Mission 86\n5.2 Opportunity #2: Developing and Implementation Plan 87\n5.3 Opportunity #2.1: Improved communication and coordination with\nMission stakeholders 89\n5.4 Opportunity #2.2: Increased funding for biology and basic research 90\n5.5 Opportunity #2.3: Innovated funding to retain early and mid-stage\nresearchers and clinician researchers 91\n5.6 Opportunity #2.4: Alternative innovating funding models 93\n5.7 Opportunity #2.5: Encouraging greater Industry involvement 94\n5.8 Opportunity #2.6: Aligning future funding with best role for the Mission 95\n5.9 Opportunity #2.7: Consumer engagement framework 96\n5.10 Opportunity #3: Improvements to the competitive grants model 97\nA.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 10]\n4\nReview of the Australian Brain Cancer Mission\n1 Overview of the review\nThe purpose of this review in line with the Terms of Reference is to:\n■ assess all existing investments under the Mission through the MRFF and partner\nfunding3 from October 2017 to April 2022\n■ assess all other existing investments in brain cancer research made through the\nMRFF from October 2017 to April 2022\n■ consider approaches and the current landscape for health and medical research and\ntreatments for brain cancer internationally and in Australia, and\n■ suggest opportunities (if any) for improving alignment between the intended goals\nand implementation of the Mission.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Survival is\nparticularly poor for certain brain cancer types, with the five year survival rate for\nglioblastoma being 4.6 per cent.22\nThe relatively minimal progress in survival reflects the absence of substantive change in\nthe treatment regime for brain cancer in the last 30 years, and treatments that do exist,\nresult often result in a range of physical and mental health problems.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 49]\nReview of the Australian Brain Cancer Mission\n43\n2.12 Funds committed by funding categories — Funding Partners\n- Amount committed Share of total\n- $ million Per cent\nCentres of Excellence 26.03 35\nClinical trials 13.01 18\nClinical trial capacity 6.65 9\nEquipment grant 5.06 7\nFellowships 3.07 4\nResearch chairs 1.00 1\nResearch grants 16.12 22\nStaff 0.36 0\nTechnology research 2.02 3\nOther 0.65 1\nTotal 73.97 100\nNote: The relevant information is not available for all Funding Partners .\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- 5\n3\n3\n2\ne v ie\nw\no f\nth\ne\nA\nu\ns tra\nlia\nn\nB\nra\nResearch Grants Addressing survivorship and palliative care needs in Queensland University of 0.32 in\nC\nchildren and adolescents with brain cancer Technology a n\nc\ne\nr\nM\nResearch Grants Developing novel therapeutic approaches for treatment The University of 1.01 is\ns\nof vincristine-induced neuropathy Queensland io\nn\nResearch Grants Risk factors for speech and language impairments and Queensland University of 0.33\nlong term outcomes in survivors of childhood primary Technology\nposterior fossa tumours\nResearch Grants Embryonal Tumours with Multilayered Rosettes - basic The University of 0.20\nbiology and tools for translation Queensland\nResearch Grants Shared Program Resources for Centre for Child and The University of 1.00\nAdolescent Brain Cancer Research Queensland; Queensland\nUniversity of Technology;\nQIMR Berghofer & CHQ\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- B ra\nin\nC\nResearch grant Targeting the DC-T cell axis to treat glioblastoma, Dr Royal Adelaide Hospital 0.30 a\nn\nTessa Garret c e\nr\nM\nis\nResearch grant Discovering new ways to treat deadly childhood brain Telethon Kids Institute 0.12 s io\ncancers by understanding the immune system, n\nA/Professor Raelene Endesby\nResearch grant A new and effective combination therapy for children Institute of Molecular 0.24\nwith brain cancer, Professor Brandon Wainwright Bioscience\nFellowships Polyamine pathway inhibition as a targeted therapy for Children's Cancer 0.46\nMYC-amplified medulloblastoma in paediatric patients, Institute\nAaminah Khan\nFellowships Developing novel treatments for high-risk childhood brain Kids Cancer Centre 0.28\ncancer, Dr Marion Mateos Sydney Children’s\nHospital\nFellowships Precision neurosurgical image-guidance: improving the Murdoch Children’s 0.28\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 2]\nFunding\nFunding Partner investment Institution contribution\n(million)\nThe Brain Cancer Centre WEHI $4.00\nChildren's Hospital Foundation Queensland\nExploiting CDK 4/6 inhibition to treat medulloblastoma University of Queensland $0.20\nNew strategies for targeting immune evasion in children's brain tumours University of Queensland $0.10\nIntegrating innovative models of the brain microenvironment to identify new treatment strategies for\nUniversity of Queensland $0.05\nmedulloblastoma\nThe University of Queensland;\nUnallocated - research tbc Queensland; University of $1.11\nTechnology; QIMR Berghofer & CHQ\nAssessment of the Novel OLIG2 Inhibitor CT179 as an EffectiveTherapy for Paediatric Medulloblastoma QIMR Berghofer $0.50\nEphA3 a Valid Tumour Specific Therapeutic Target for Paediatric Brain Cancer QIMR Berghofer $0.53\nQueensland University of\n Source: `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)`\n- [Page 5]\nFunding\nFunding Partner investment Institution contribution\n(million)\nA new and effective combination therapy for children with brain cancer, Professor Brandon Wainwright Institute of Molecular Bioscience $0.24\nPolyamine pathway inhibition as a targeted therapy for MYC-amplified medulloblastoma in paediatric\nChildren's Cancer Institute $0.46\npatients, Aaminah Khan\nKids Cancer Centre Sydney Children’s\nDeveloping novel treatments for high-risk childhood brain cancer, Dr Marion Mateos $0.28\nHospital\nPrecision neurosurgical image-guidance: improving the outcomes of childhood brain tumour surgery using Murdoch Children’s Research\n$0.28\nartificial intelligence-based automated MRI tractography, Joseph Yuan-Mou Yang Institute\nDissecting drug resistance and guiding targeted therapy in paediatric gliomas -PhD Scholarsip top-up, Philipp\nChildren's Cancer Institute $0.04\nGraber\n Source: `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf (https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf)`\n- Access the report\nNews\nNews\nWebinar: Sex, gender, variations of sex characteristics and sexual orientation in health and medical research\n17 November 2025\nExpress your interest in guiding the Medical Research Future Fund’s Reducing Health Inequities Mission\n19 August 2025\nMedical Research Future Fund: Supporting researchers to tackle Australia’s health priorities\n11 August 2025\nView more news\nRelated work\nRelated work\nCo-design of an Enhanced Consumer Engagement Process for Health Technology Assessment\nThis process developed recommendations to include the patient and consumer voice earlier in the Health Technology Assessment (HTA) process.\n Source: `pages/strategies-index__10.html (https://www.health.gov.au/topics/health-technologies-and-digital-health?language=en)`\n- [Page 4]\niv\nReview of the Australian Brain Cancer Mission\nCommunity engagement with new technologies/treatments 81\nCommercialisation of research outcomes 82\n5 Opportunities for the future 84\nOpportunities overview 84\nLeadership in brain cancer research 85\nImplementation Plan for the Mission 87\nImproved communication and coordination 88\nGaps for future Mission focus 89\nFuture funding models to consider 91\nFuture funding focus 94\nConsumer engagement framework 95\nScope for administrative improvements 96\nReferences 98\nAPPENDICES 101\nA Brain cancer research grants awarded by the MRFF 103\nB Summary of Funding Partner investments 110\nC Review method 120\nD Key areas of brain cancer research and treatments 125\nE US style cradle to grave research grants 133\nBOXES, CHARTS AND TABLES\n1 Overview of the review 4\n2 Brain cancer specific projects and programs 2003-2005 to 2018-2020 6\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Based on the 2023 Cancer Australia audit of cancer research in Australia, in 2003-2005,\n$1.5 million was allocated to 10 brain cancer specific projects.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- The outcomes of the ICRP data compared with the\nCancer Australia audit of Australian brain cancer research funding reveal that Australia\nhas:\n■ a larger focus on treatment (51 per cent of total projects), compared to 34 per cent\ninternationally\n■ a larger focus on early detection, diagnosis and prognosis (26 per cent), compared to\n18 per cent internationally\n■ a larger focus on survivorship (13 per cent), compared to 8 per cent internationally\n■ a substantially smaller focus on biology (9 per cent of projects), compared to 24 per\ncent internationally10, and\n■ no focus on aetiology and prevention, which internationally comprises 16 per cent of\ntotal projects.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 15]\nReview of the Australian Brain Cancer Mission\n9\n4 ICRP brain cancer projects by CSO and Cancer Australia Audit of Australian brain\ncancer funding, 2018-2020\nICRP Treatment CA Audit\n5% Biology 0% 0%\n9% 13%\n34% Early Detection, Diag. &\n10%\nProg.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- 2.17 ICRP brain cancer projects by CSO and Cancer Australia Audit of Australia brain\ncancer funding, 2018-2020\nICRP Treatment CA Audit\n5% Biology 0% 0%\n9% 13%\n34% Early Detection, Diag. &\n10%\nProg.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 65]\nReview of the Australian Brain Cancer Mission\n59\n3.9 Alignment of projects with Roadmap — Increased patient survival, quality of life\nand care experiences\nABCM grants - close alignment Other MRFF grants - close alignment\nABCM grants - some relevance Other MRFF grants - some relevance\nInvest in survivorship research to better understand the\nlifelong impact of a brain cancer diagnosis\nDefine patient navigator roles and work with\ngovernments to improve transport and other support\nschemes\nAudit and build national care standards, support\ndecision-making, and articulate clinical pathways for\npatients\nPromote the benefits of surgery or treatment at centres\nof clincial excellence, and the merits of immediate\nreferral\n0 2 4 6 8 10 12 14 16 18\nNo. of projects\nData source: CIE Survey.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Key cancer databases were also examined, including:\n■ the International Cancer Research Partnership (ICRP), which is an alliance of cancer\nresearch organisations from Australia, Canada, France, Japan, the Netherlands,\nUnited Kingdom, and the United States, which maintains the only public source,\nworldwide, of current and past grants, totalling over $80 billion in cancer research\nsince 2000 from 32 ICRP Partners and 156 international funding organisations78\n■ the 2023 Cancer Australia Audit of cancer research projects and programs in\nAustralia over the last three triennia (2012-2014, 2015-2017 and 2018-2020)79\n■ the Australian New Zealand Clinical Trials Registry (ANZCTR), which is an online\npublic registry of clinical trials, held at the NHMRC Clinical Trials Centre, University\nof Sydney, and\n■ ClinicalTrials.gov80, which is run by the United States National Library of Medicine\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- The work has led to the 2021 publication\nof ‘Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively\neliminate human glioblastoma’98 and the 2020 publication of ‘De novo designed receptor\ntransmembrane domains enhance CAR-T cell cytotoxicity and attenuate cytokine release’99\n■ Genetic research — seeking more information about specific gene mutations and how\nthey relate to the risk and growth of a brain tumour so that precision medicine\napproaches that target tumour-specific mutations can be explored.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- E.1 US Department of Defence grant funding structure\nAward Key Mechanism Elements Funding\nMechanism\nConcept Award ■ Supports highly innovative, non-incremental, high ■ Maximum funding of\nrisk/potentially high-reward lung cancer research. $100,000 in direct costs\n(plus indirect costs).\n■ Emphasis on innovation.\n■ Period of performance\n■ Clinical trials are not allowed.\nshould not exceed 1 year\n■ Preliminary data are not required.\n■ Relevance to military health is strongly encouraged.\n■ Care Delivery and Health Disparity category must address one\nor more of the Disparities, Health Outcomes, and Survivorship\nAreas of Emphasis.\n■ Cancer Research Continuum category must address at least\none or more of the nine cancer continuum-focused Areas of\nEmphasis.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n\n## Corporate Values and Operating Culture\n\n- [Page 114]\n108\nReview of the Australian Brain Cancer Mission\nPrinciple Outcome Elements\nPrinciple 5: ■ National collection and reporting of key ■ Consumer and carer experience, treatment and\nData-driven cancer data, including consumer outcome data are routinely captured and consistently\nimprovemen experience and outcome data, provides reported for accountability and to improve quality of\nts and an indicator for high-quality care, care.\ninvestment influences health service improvements\n■ Research in cancer survivorship is translated to inform\nin research and informs investment in research\npractice, innovation and improvement in cancer care.\n■ Published research in cancer\nsurvivorship enriches the evidence\nbase and informs improvements to\nenhance the care and outcomes of\npeople affected by cancer\nSource: Cancer Australia 2017, Principles of Cancer Survivorship\nhttps://www.canceraustralia.\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [Page 117]\nB.1 Funding partner contributions to the Australian Brain Cancer Mission (July 2023)\nFunding contribution ($m)\nCommitted Total\nFunding Category of MRFF Other to projects to committed\npartner funding Activity Institution projects projects date to Mission*\nACT Health and Staff Provision of a Brain Cancer Specialist Nurse Canberra Health Service 0.36 1.82 3.95\nCanberra\nHealth Services Equipment grant Provision of stereotactic treatment Canberra Health Service 0.30\nOther Brain tumour multi-disciplinary team meeting Canberra Health Service 0.29\nOther Brain tumour multi-disciplinary meeting Canberra Health Service 0.14\nClinical trial Canberra Health services research and clinical trials Canberra Health Service 0.14\nResearch grant Research grant: Research and innovation fund ACT Health Directorate 0.29\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- Reportable Gifts and Benefits – 1 January to 31 March 2026\n28 April 2026\nDataset\nThis dataset reports gifts and benefits accepted in the performance of official duties that are valued over $100 (excluding GST), to meet whole‑of‑government reporting requirements set by the Australian Public Service Commission.\n Source: `pages/about.html (https://www.health.gov.au/topics/about-the-department)`\n- Filter results\nYou can narrow down the results using the filters\nType\nCampaign\n(30)\nInitiative\n(303)\nProgram\n(85)\nReform\n(13)\nReview\n(25)\nAudience\nGeneral public\n(366)\nHealthcare workers\n(7)\nHealth professionals\n(76)\nIndustry\n(18)\nProviders\n(39)\nStudents and trainees\n(17)\nTopics\nAboriginal and Torres Strait Islander health\n(30)\nAboriginal and Torres Strait Islander health workforce\n(12)\nAbout the department\n(2)\nAged care\n(78)\nAged care workforce\n(15)\nAlcohol\n(3)\nAllied health care\n(17)\nBladder and bowel\n(4)\nBlood and blood products\n(2)\nCancer\n(16)\nChildren's health\n(14)\nChronic conditions\n(17)\nCommunicable diseases\n(6)\nDementia\n(12)\nDental health\n(1)\nDentists and dental practitioners\n(3)\nDisability and carers\n(35)\nDrugs\n(4)\nEar health and hearing\n(5)\nEmergency health management\n(5)\nEye health and vision\n(2)\nFamily, domestic and sexual violence\n(4)\nFood and nutrition\n(5)\nGeneral practice\n Source: `pages/priorities-index.html (https://www.health.gov.au/our-work)`\n- Subscribe\nNews\nNews\nTraining and professional development opportunities for aged care workers\n11 March 2026\nAged Care Provider Workforce Survey\n9 February 2026\nEOI: Support at Home pooled funding trial workshops\n29 October 2025\nView more news\nResources\nPrinciple 3 - Access the Outdoors: National Aged Care Design and Guidelines Webinar Series: Home Matters - Rethinking Aged Care Design\n30 April 2026\nPresentation\nThis webinar is for people working in aged care and design.\n Source: `pages/priorities-index__12.html (https://www.health.gov.au/our-work/aged-care-reforms?language=en)`\n- Interests may be:\n• Financial – if it is likely that the member could make an appreciable financial gain or\nloss.1\n• Professional – involvement with organisations with a direct interest in or relevance\nto the MRFF, including:\nmembership\no\naffiliation\no\nbeing a representative.2\no\n1 Adapted from the Pecuniary Interest Tribunal website: https://www.findlaw.com.au/articles/1694/the-\npecuniary-interest-tribunal.aspx\n2 Adapted from NHMRC’s Identifying and managing conflicts of interest:\nhttps://www.nhmrc.gov.au/guidelinesforguidelines/plan/identifying-and-managing-conflicts-interest\n1\n Source: `other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf (https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf)`\n- [Page 3]\nReview of the Australian Brain Cancer Mission\niii\nContents\nGlossary 1\nSummary 3\nAbout the Australian Brain Cancer Mission 3\nOverview of the Australian brain cancer research landscape 5\nMission progress and key achievements to date 10\nKey opportunities 14\nResearch qualifications and limitations 18\n1 Introduction 20\nUnmet need in brain cancer research 20\nThe Australian Brain Cancer Mission 21\nAbout this review 25\nMethodology 27\nResearch qualifications and limitations 28\n2 Local and international approaches to research 30\nOverview of Australian brain cancer research 30\nFunders of Australian brain cancer research 34\nAustralian research affiliations 45\nFunding models for Australian brain cancer research 48\nComparisons with international brain cancer research 51\n3 Mission and other MRFF brain cancer research 53\nMRFF-funded brain cancer research 53\nFocus on collaboration 56\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n- [pages 5,6,7,8,9]\ncapacity and excellence 61\n3.13 Funding partner research grant value — frequency distribution 62\n4.1 Capacity built through MRFF grants and future clinical trial activity 69\n4.2 Likelihood of delivering a new health technology 70\n4.3 Types of new health technologies developed through MRFF brain cancer\ngrants 71\n4.4 Likelihood of new technologies becoming embedded in health practices 71\n4.5 Potential impact of new technologies 72\n4.6 Likelihood of MRFF grants leading to new health interventions 73\n4.7 Types of new health interventions 74\n4.8 Likelihood of new interventions becoming embedded in health practices 75\n4.9 Ways MRFF-funded research projects have built Australian research\ncapacity 76\n4.10 Likelihood an intervention will lead to faster adoption of best practice 80\nwww.TheCIE.com.au\n Source: `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py ` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `strategies/australian-brain-cancer-research-roadmap.pdf` - strategies - https://www.health.gov.au/sites/default/files/documents/2022/07/australian-brain-cancer-research-roadmap.pdf\n- `strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf` - strategies - https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf\n- `strategies/mrff-australian-brain-cancer-mission-strategic-documents.pdf` - strategies - https://www.health.gov.au/sites/default/files/2025-03/mrff-australian-brain-cancer-mission-strategic-documents.pdf\n- `strategies/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf` - strategies - https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf\n- `pages/about.html` - pages - https://www.health.gov.au/topics/about-the-department\n- `pages/announcements-index.html` - pages - https://www.health.gov.au/node/8723\n- `pages/announcements-index__13.html` - pages - https://www.health.gov.au/resources/publications/medical-research-future-fund-declaration-of-interest-policy-statement?language=en\n- `pages/announcements-index__14.html` - pages - https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf\n- `pages/announcements-index__15.html` - pages - https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.docx\n- `pages/announcements-index__16.html` - pages - https://www.health.gov.au/about-us/corporate-reporting/our-commitments/ai-transparency-statement\n- `pages/contact.html` - pages - https://www.health.gov.au/contacts/australian-brain-cancer-mission-contact?language=en\n- `pages/homepage.html` - pages - https://www.health.gov.au/committees-and-groups/australian-brain-cancer-mission-expert-advisory-panel\n- `pages/ministers.html` - pages - https://www.health.gov.au/ministers\n- `pages/news-latest.html` - pages - https://www.health.gov.au/news\n- `pages/priorities-index.html` - pages - https://www.health.gov.au/our-work\n- `pages/priorities-index__12.html` - pages - https://www.health.gov.au/our-work/aged-care-reforms?language=en\n- `pages/publications-index.html` - pages - https://www.health.gov.au/resources/publications/review-of-the-australian-brain-cancer-mission\n- `pages/strategies-index.html` - pages - https://www.health.gov.au/resources/publications/mrff-australian-brain-cancer-mission-strategic-documents?language=en\n- `pages/strategies-index__00.html` - pages - https://www.health.gov.au/resources/publications/mrff-australian-brain-cancer-mission-strategic-documents?language=en\n- `pages/strategies-index__01.html` - pages - https://www.health.gov.au/resources/publications/australian-brain-cancer-research-roadmap?language=en\n- `pages/strategies-index__02.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/mrff-australian-brain-cancer-mission-strategic-documents.pdf\n- `pages/strategies-index__03.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/mrff-australian-brain-cancer-mission-strategic-documents.docx\n- `pages/strategies-index__04.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf\n- `pages/strategies-index__05.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025_0.docx\n- `pages/strategies-index__06.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november_2024.pdf\n- `pages/strategies-index__07.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november_2024.docx\n- `pages/strategies-index__08.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf\n- `pages/strategies-index__09.html` - pages - https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.docx\n- `pages/strategies-index__10.html` - pages - https://www.health.gov.au/topics/health-technologies-and-digital-health?language=en\n- `pages/taskforces-index.html` - pages - https://www.health.gov.au/committees-and-groups/australian-brain-cancer-mission-expert-advisory-panel\n- `other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf\n- `other-pdfs/review-of-the-australian-brain-cancer-mission.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf\n- `other-pdfs/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/2025-03/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november_2024.pdf\n- `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf` - other-pdfs - https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.\n- No annual report text source found.\n- No global comparison/case-study sources found.", "legislation_md": "# MRFF Australian Brain Cancer Mission Expert Advisory Panel - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:26:22.593305+00:00\n**Entity ID**: B-004497\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 34\n- Unique legislation references found: 1\n\n| Type | Count |\n|---|---:|\n| Act | 1 |\n\n## Legislation References\n\n### Medical Research Future Fund Act 2015\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Medical+Research+Future+Fund+Act+2015\n\n**Sources**:\n- `other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pages.jsonl`\n\n**Evidence contexts**:\n- apted from ATAGI declaration of member interests form\n4 Where a Chair declares a conflict of interest, alternative chairing arrangements will be put in place utilising\nthe Co-Chair, Deputy Chair or another member of the group as necessary\n5 Section 32K of the Medical Research Future Fund Act 2015 prescribes certain additional requirements for\nmembers of the Australian Medical Research Advisory Board (AMRAB) regarding the disclosure of interests.\nAMRAB, in performing its functions, is accountable to the Minister for Health.\n2\n\n[page 3]\nIn some cases, c\n Source: `other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pages.jsonl`\n\n## Files Scanned\n\n- `pages/about.html` (page)\n- `pages/announcements-index.html` (page)\n- `pages/announcements-index__13.html` (page)\n- `pages/announcements-index__14.html` (page)\n- `pages/announcements-index__15.html` (page)\n- `pages/announcements-index__16.html` (page)\n- `pages/contact.html` (page)\n- `pages/homepage.html` (page)\n- `pages/ministers.html` (page)\n- `pages/news-latest.html` (page)\n- `pages/priorities-index.html` (page)\n- `pages/priorities-index__12.html` (page)\n- `pages/publications-index.html` (page)\n- `pages/strategies-index.html` (page)\n- `pages/strategies-index__00.html` (page)\n- `pages/strategies-index__01.html` (page)\n- `pages/strategies-index__02.html` (page)\n- `pages/strategies-index__03.html` (page)\n- `pages/strategies-index__04.html` (page)\n- `pages/strategies-index__05.html` (page)\n- `pages/strategies-index__06.html` (page)\n- `pages/strategies-index__07.html` (page)\n- `pages/strategies-index__08.html` (page)\n- `pages/strategies-index__09.html` (page)\n- `pages/strategies-index__10.html` (page)\n- `pages/taskforces-index.html` (page)\n- `other-pdfs/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november.pages.jsonl` (pdf_pages)\n- `other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pages.jsonl` (pdf_pages)\n- `other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pages.jsonl` (pdf_pages)\n- `other-pdfs/review-of-the-australian-brain-cancer-mission.pages.jsonl` (pdf_pages)\n- `strategies/australian-brain-cancer-research-roadmap.pages.jsonl` (pdf_pages)\n- `strategies/mrff-australian-brain-cancer-mission-strategic-documents.pages.jsonl` (pdf_pages)\n- `strategies/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pages.jsonl` (pdf_pages)\n- `strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pages.jsonl` (pdf_pages)", "global_initiatives_md": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": null, "purposes_source_page": null, "how_we_deliver": null, "how_we_deliver_source_page": null, "government_priorities": [], "outcomes": [ { "name": "AIM 1: Improve understanding of brain cancer biology", "description": "To conduct innovative, interdisciplinary, collaborative and translational preclinical brain cancer research projects that advance knowledge in at least one of these areas:\n• Aetiology of brain cancer;\n• Identification and validation of new therapeutic strategies for brain cancer; and/or\n• Development of new therapies for brain cancer.", "key_activities": [ "Conduct innovative, interdisciplinary, collaborative and translational preclinical brain cancer research projects", "Adopt innovative approaches to brain cancer research", "Empower and champion Early- and Mid-Career Researchers", "Involve health care services, including regional, rural and remote health care services" ], "source_page": 4 }, { "name": "AIM 2: Improve survival for children and adults with brain cancer", "description": "To conduct innovative, interdisciplinary, collaborative and translational pre-clinical and/or early-stage clinical brain cancer research projects that advance knowledge in at least two of these areas:\n• Aetiology of brain cancer;\n• Identification and validation of new therapeutic strategies for brain cancer; and/or\n• Development of new therapies for brain cancer.", "key_activities": [ "Conduct innovative, interdisciplinary, collaborative and translational pre-clinical and/or early-stage clinical brain cancer research projects", "Adopt innovative approaches to brain cancer research", "Empower and champion Early- and Mid-Career Researchers", "Involve health care services, including regional, rural and remote health care services" ], "source_page": 6 }, { "name": "AIM 3: Improve quality of life for people affected by brain cancer", "description": "To develop novel approaches to reduce treatment toxicity and adverse effects of brain cancer treatment for patients, to minimise the short- and/or long-term negative impacts for patients and carers.", "key_activities": [ "Measure the negative impacts of brain cancer treatments", "Improve the quality of life for people affected by brain cancer", "Empower and champion Early- and Mid-Career Researchers", "Involve health care services, including regional, rural and remote health care services" ], "source_page": 7 } ], "values": [ "Innovation", "Collaboration", "Support for Researchers", "Equity" ], "values_framework_name": "Not specified", "kpi_targets_2025_26": [ { "code": "AIM1-1", "measure": "Understanding the factors associated with the aetiology of brain cancer", "target": "Improve understanding of brain cancer biology", "source_page": 4 }, { "code": "AIM1-2", "measure": "Understanding factors associated with the mechanisms of treatment resistance", "target": "Improve understanding of brain cancer biology", "source_page": 4 }, { "code": "AIM2-1", "measure": "Identifying and developing new therapeutic strategies for brain cancer", "target": "Improve survival for children and adults with brain cancer", "source_page": 6 }, { "code": "AIM2-2", "measure": "Improving diagnostic strategies for disease identification and treatment monitoring", "target": "Improve survival for children and adults with brain cancer", "source_page": 6 }, { "code": "AIM3-1", "measure": "Creating and evaluating innovative approaches for improving the quality of life of people affected by brain cancer", "target": "Improve quality of life for people affected by brain cancer", "source_page": 7 } ], "kpi_results_2024_25": [], "_source_urls": { "annual_report_url": "", "corporate_plan_url": "" } }, "ideas": [ { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "E.1 US Department of Defence grant funding structure\nAward Key Mechanism Elements Funding\nMechanism\nConcept Award ■ Supports highly innovative, non-incremental, high ■ Maximum funding of\nrisk/potentially high-reward lung cancer research. $100,000 in direct costs\n(plus indirect costs).\n■ Emphasis on innovation.\n■ Period of performance\n■ Clinical trials are not allowed.\nshould not exceed 1 year\n■ Preliminary data are not required.\n■ Relevance to military health is strongly encouraged.\n■ Care Delivery and Health Disparity category must address one\nor more of the Disparities, Health Outcomes, and Survivorship\nAreas of Emphasis.\n■ Cancer Research Continuum category must address at least\none or more of the nine cancer continuum-focused Areas of\nEmphasis.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "E.1 US Department of Defence grant funding structure\nAward Key Mechanism Elements Funding\nMechanism\nConcept Award ■ Supports highly innovative, non-incremental, high ■ Maximum funding of\nrisk/potentially high-reward lung cancer research. $100,000 in direct costs\n(plus indirect costs).\n■ Emphasis on innovation.\n■ Period of performance\n■ Clinical trials are not allowed.\nshould not exceed 1 year\n■ Preliminary data are not required.\n■ Relevance to military health is strongly encouraged.\n■ Care Delivery and Health Disparity category must address one\nor more of the Disparities, Health Outcomes, and Survivorship\nAreas of Emphasis.\n■ Cancer Research Continuum category must address at least\none or more of the nine cancer continuum-focused Areas of\nEmphasis.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Procurement & Delivery", "scale": "small", "title": "Procurement lessons library for repeat purchases", "idea": "Capture reusable procurement clauses, market lessons, supplier performance notes, and common evaluation criteria.", "quote": "[Page 10]\nOpportunities to use additional investment and other research to support\nthe priority areas include, but are not limited to, the following:\n• Mission Funding Partner investments\n• MRFF initiatives, Missions and grant opportunities (such as the Emerging Priorities and\nConsumer-Driven Research Initiative's 2024 Paediatric Brain Cancer Research Grant\nOpportunity, Genomics Health Futures Mission, Clinical Trials Activity initiative, Research\nData Infrastructure, National Critical Research Infrastructure, MRFF funding for rural\nresearch streams, and the Early to Mid-Career Researchers initiative)\n• The Australian Government through:\nthe National Health and Medical Research Council (NHMRC)\no\nthe Australian Research Council\no\nCancer Australia\no\nother government investment\no\n• State and territory governments\n• Corporate, philanthropic and investment funds", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Delivery teams / suppliers", "source": "strategies/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf (https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Procurement & Delivery", "scale": "large", "title": "Portfolio delivery office for major investments", "idea": "Stand up a portfolio delivery office that tracks benefits, risks, dependencies, procurement, and delivery confidence.", "quote": "[Page 10]\nOpportunities to use additional investment and other research to support\nthe priority areas include, but are not limited to, the following:\n• Mission Funding Partner investments\n• MRFF initiatives, Missions and grant opportunities (such as the Emerging Priorities and\nConsumer-Driven Research Initiative's 2024 Paediatric Brain Cancer Research Grant\nOpportunity, Genomics Health Futures Mission, Clinical Trials Activity initiative, Research\nData Infrastructure, National Critical Research Infrastructure, MRFF funding for rural\nresearch streams, and the Early to Mid-Career Researchers initiative)\n• The Australian Government through:\nthe National Health and Medical Research Council (NHMRC)\no\nthe Australian Research Council\no\nCancer Australia\no\nother government investment\no\n• State and territory governments\n• Corporate, philanthropic and investment funds", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Delivery teams / suppliers", "source": "strategies/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf (https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Citizen Participation", "scale": "small", "title": "Consultation feedback summaries with response tracking", "idea": "Summarise consultation submissions by theme and publish what changed in response.", "quote": "Development of an evaluation and stakeholder management plan\nAn evaluation and stakeholder management plan were developed for this review which:\n■ set out a fit-for-purpose program logic (see chart 1.4) that aligns with the MRFF\nMonitoring, Evaluation and Learning Strategy 2021-22 to 2023-24 (Evaluation\nStrategy) to review progress towards MRFF outcome and impact measures, and\nalignment with the goals and priorities of the Mission\n■ provided a search strategy for the literature review to support an environmental scan\nof the brain cancer research landscape\n■ identified how literature would be collated and assessed to draw insight for the\npurpose of the Mission evaluation, and\n■ set out a proposed consultation strategy, including the type of information to be\ncollected from surveys, and from semi-structured interviews.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Citizen Participation", "scale": "large", "title": "Always-on policy participation platform", "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.", "quote": "Development of an evaluation and stakeholder management plan\nAn evaluation and stakeholder management plan were developed for this review which:\n■ set out a fit-for-purpose program logic (see chart 1.4) that aligns with the MRFF\nMonitoring, Evaluation and Learning Strategy 2021-22 to 2023-24 (Evaluation\nStrategy) to review progress towards MRFF outcome and impact measures, and\nalignment with the goals and priorities of the Mission\n■ provided a search strategy for the literature review to support an environmental scan\nof the brain cancer research landscape\n■ identified how literature would be collated and assessed to draw insight for the\npurpose of the Mission evaluation, and\n■ set out a proposed consultation strategy, including the type of information to be\ncollected from surveys, and from semi-structured interviews.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "[Page 117]\nB.1 Funding partner contributions to the Australian Brain Cancer Mission (July 2023)\nFunding contribution ($m)\nCommitted Total\nFunding Category of MRFF Other to projects to committed\npartner funding Activity Institution projects projects date to Mission*\nACT Health and Staff Provision of a Brain Cancer Specialist Nurse Canberra Health Service 0.36 1.82 3.95\nCanberra\nHealth Services Equipment grant Provision of stereotactic treatment Canberra Health Service 0.30\nOther Brain tumour multi-disciplinary team meeting Canberra Health Service 0.29\nOther Brain tumour multi-disciplinary meeting Canberra Health Service 0.14\nClinical trial Canberra Health services research and clinical trials Canberra Health Service 0.14\nResearch grant Research grant: Research and innovation fund ACT Health Directorate 0.29", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "[Page 117]\nB.1 Funding partner contributions to the Australian Brain Cancer Mission (July 2023)\nFunding contribution ($m)\nCommitted Total\nFunding Category of MRFF Other to projects to committed\npartner funding Activity Institution projects projects date to Mission*\nACT Health and Staff Provision of a Brain Cancer Specialist Nurse Canberra Health Service 0.36 1.82 3.95\nCanberra\nHealth Services Equipment grant Provision of stereotactic treatment Canberra Health Service 0.30\nOther Brain tumour multi-disciplinary team meeting Canberra Health Service 0.29\nOther Brain tumour multi-disciplinary meeting Canberra Health Service 0.14\nClinical trial Canberra Health services research and clinical trials Canberra Health Service 0.14\nResearch grant Research grant: Research and innovation fund ACT Health Directorate 0.29", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "2.17 ICRP brain cancer projects by CSO and Cancer Australia Audit of Australia brain\ncancer funding, 2018-2020\nICRP Treatment CA Audit\n5% Biology 0% 0%\n9% 13%\n34% Early Detection, Diag. &\n10%\nProg.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "2.17 ICRP brain cancer projects by CSO and Cancer Australia Audit of Australia brain\ncancer funding, 2018-2020\nICRP Treatment CA Audit\n5% Biology 0% 0%\n9% 13%\n34% Early Detection, Diag. &\n10%\nProg.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf (https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Regulation & Policy", "scale": "small", "title": "Regulatory burden scan for forms, guidance, and reporting", "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.", "quote": "[pages 1,2,3,4,5]\n[Page 1]\nDeclarations of Interest Policy Statement\nPurpose\nTo ensure members of MRFF advisory panels, committees, groups and other bodies identify\nand declare relevant interests and that the Health and Medical Research Office (HMRO)\nmanages these interests appropriately.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf (https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "category": "Regulation & Policy", "scale": "large", "title": "Adaptive regulation program with live feedback loops", "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.", "quote": "[pages 1,2,3,4,5]\n[Page 1]\nDeclarations of Interest Policy Statement\nPurpose\nTo ensure members of MRFF advisory panels, committees, groups and other bodies identify\nand declare relevant interests and that the Health and Medical Research Office (HMRO)\nmanages these interests appropriately.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Regulated entities / policy teams", "source": "other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf (https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] } ], "legislation_administered": [], "artifacts": [ { "category": "strategies", "year": "2025", "url": "https://www.health.gov.au/sites/default/files/2025-03/mrff-australian-brain-cancer-mission-strategic-documents.pdf", "file": "strategies/mrff-australian-brain-cancer-mission-strategic-documents.pdf", "bytes": 275077, "link_text": "MRFF Australian Brain Cancer Mission strategic documents [PDF - 269 KB] - 2 pages" }, { "category": "strategies", "year": "2025", "url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "file": "strategies/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "bytes": 490435, "link_text": "MRFF Australian Brain Cancer Mission strategic documents [PDF - 479 KB] - 10 pages" }, { "category": "strategies", "year": "2022", "url": "https://www.health.gov.au/sites/default/files/documents/2022/07/australian-brain-cancer-research-roadmap.pdf", "file": "strategies/australian-brain-cancer-research-roadmap.pdf", "bytes": 362448, "link_text": "Australian Brain Cancer Research Roadmap [PDF - 354 KB] - 2 pages" }, { "category": "strategies", "year": "2024", "url": "https://www.digital.gov.au/sites/default/files/documents/2024-08/Standard%20for%20AI%20transparency%20statements%20v1.1.pdf", "file": "strategies/Standard-20for-20AI-20transparency-20statements-20v1.1.pdf", "bytes": 289017, "link_text": "Standard for AI transparency statements" }, { "category": "other-pdfs", "year": "2025", "url": "https://www.health.gov.au/sites/default/files/2025-03/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november_2024.pdf", "file": "other-pdfs/appendix_a_-_mrff_australian_brain_cancer_mission_projects_funded_as_of_november.pdf", "bytes": 118488, "link_text": "MRFF Australian Brain Cancer Mission strategic documents [PDF - 116 KB] - 3 pages" }, { "category": "other-pdfs", "year": "2025", "url": "https://www.health.gov.au/sites/default/files/2025-03/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_mission_as_of_november_2024.pdf", "file": "other-pdfs/appendix_b_-_funding_partner_contributions_to_the_australian_brain_cancer_missio.pdf", "bytes": 179395, "link_text": "MRFF Australian Brain Cancer Mission strategic documents [PDF - 176 KB] - 10 pages" }, { "category": "other-pdfs", "year": "2023", "url": "https://www.health.gov.au/sites/default/files/2023-12/review-of-the-australian-brain-cancer-mission.pdf", "file": "other-pdfs/review-of-the-australian-brain-cancer-mission.pdf", "bytes": 1701496, "link_text": "Review of the Australian Brain Cancer Mission [PDF - 2 MB] - 142 pages" }, { "category": "other-pdfs", "year": "2021", "url": "https://www.health.gov.au/sites/default/files/documents/2021/12/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf", "file": "other-pdfs/medical-research-future-fund-declaration-of-interest-policy-statement_0.pdf", "bytes": 286828, "link_text": "Medical Research Future Fund Declaration of Interest Policy Statement [PDF - 281 KB] - 5 pages" } ], "_meta": { "snapshot_built_at": "2026-05-13T11:02:55+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "strategies\\mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.txt", "url": "https://www.health.gov.au/sites/default/files/2025-03/mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025.pdf", "year": "mrff_australian_brain_cancer_mission_implementation_plan_-_february_2025" }, "usage": { "input_tokens": 4104, "output_tokens": 945, "total_tokens": 5049, "model": "nova-micro" }, "cost_usd": 0.00027594, "elapsed_seconds": 4.8, "generated_at": "2026-05-13T05:17:28+00:00" }, "ideas_manifest": { "entity_id": "B-004497", "entity_name": "MRFF Australian Brain Cancer Mission Expert Advisory Panel", "folder_name": "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel", "generated_at": "2026-05-09T23:06:05.637976+00:00", "idea_count": 12, "markdown": "ideas/MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "MRFF-Australian-Brain-Cancer-Mission-Expert-Advisory-Panel_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }